AL Amyloidosis

Table of Contents

  1. What is AL Amyloidosis?
  2. How Amyloid Fibrils Form
  3. The Heart: The Most Dangerous Organ Involvement
  4. Kidney Involvement: Nephrotic Syndrome
  5. Neurological Manifestations
  6. Recognizing AL Amyloidosis: The Visible Signs
  7. Diagnosis: Tissue Biopsy and Congo Red Stain
  8. Staging: Mayo 2004 and Mayo 2012 Systems
  9. Treatment: Eliminating the Plasma Cell Clone
  10. Organ Recovery and Long-Term Outcomes
  11. Liver and Gastrointestinal Involvement
  12. Research Papers
  13. Connections
  14. Featured Videos

What is AL Amyloidosis?

AL amyloidosis — also called light chain amyloidosis or primary amyloidosis — is a plasma cell dyscrasia in which a clone of abnormal plasma cells in the bone marrow overproduces misfolded immunoglobulin light chains. These light chains do not stay in the bloodstream performing their normal immune function. Instead they misfold into a distinctive protein structure — the beta-pleated sheet — that allows them to polymerize into long, rigid amyloid fibrils. Those fibrils deposit progressively in organs throughout the body, physically infiltrating and destroying tissue over months to years.

AL amyloidosis is the most common form of systemic amyloidosis in developed countries, with an estimated incidence of 10–14 cases per million persons per year in the United States. It primarily affects adults over age 50, with a slight male predominance. The condition is related to — but distinct from — multiple myeloma. Most AL amyloidosis patients have a relatively small plasma cell clone (fewer than 10% of bone marrow cells are clonal plasma cells), whereas myeloma typically involves a much larger clone with overt bone destruction, hypercalcemia, and anemia. Approximately 10–15% of AL amyloidosis patients do have concurrent myeloma meeting diagnostic criteria. The shared biology is the plasma cell origin and the production of a monoclonal immunoglobulin; the distinctive pathology in AL is that the light chains produced are unusually prone to misfolding and fibril formation.

Lambda light chains are involved approximately three times as often as kappa light chains in AL amyloidosis (roughly 3:1 lambda-to-kappa ratio). This reflects an intrinsic difference in amyloidogenicity: lambda light chains — particularly those encoded by certain variable gene segments (lambda VI subgroup is especially amyloidogenic) — have a greater tendency to adopt the beta-sheet conformation that seeds fibril growth. The specific light chain variable domain sequence determines which organs are preferentially infiltrated and how rapidly the disease progresses.

Without treatment, AL amyloidosis carries a median survival of approximately 12–15 months from diagnosis. Advanced cardiac involvement reduces this to under 6 months in the worst-stage patients. However, modern therapy targeting the plasma cell clone can halt amyloid production, allow partial organ recovery, and in some patients achieve complete hematologic remission with dramatically improved survival. Early diagnosis — before irreversible organ damage accumulates — is the most important determinant of outcome.

Back to Table of Contents

How Amyloid Fibrils Form

Understanding why AL amyloidosis causes such diverse and serious organ damage requires understanding the physical properties of amyloid fibrils — a protein conformation that is fundamentally different from normal folded proteins.

Normal Light Chain Structure

Immunoglobulin light chains are small proteins (approximately 25 kDa) that pair with heavy chains to form functional antibodies. Each light chain has a variable domain (which confers antigen specificity) and a constant domain. In normal physiology, light chains fold into compact globular structures stabilized by disulfide bonds and hydrophobic core packing. Excess light chains not incorporated into complete antibodies are secreted into the bloodstream and cleared by the kidneys.

Misfolding and the Beta-Pleated Sheet

In AL amyloidosis, certain light chain variable domain sequences are inherently unstable under physiological conditions. Instead of maintaining their compact globular fold, these chains partially unfold and re-fold into an extended beta-strand conformation. Multiple beta-strands from adjacent light chain molecules align in parallel, hydrogen-bonding together to form a cross-beta quaternary structure — the defining architecture of all amyloid fibrils regardless of the protein of origin. This cross-beta sheet runs perpendicular to the fibril axis, creating a structure of remarkable mechanical rigidity and resistance to proteolysis. Normal cellular proteases cannot efficiently degrade amyloid fibrils once formed.

Fibril Growth and Organ Deposition

Amyloid fibril formation follows nucleation-dependent polymerization kinetics: formation of a stable nucleus (oligomeric seed) is slow and rate-limiting, but once a nucleus forms, fibril elongation proceeds rapidly. Mature fibrils deposit in the extracellular matrix of organs, intercalating between normal cells and replacing functioning parenchyma with insoluble protein material. The fibrils physically disrupt organ architecture, impair electrical conduction in the heart, block glomerular filtration in the kidney, and compress nerve fibers. Serum amyloid P component (SAP), a normal plasma protein, binds to all amyloid fibrils and protects them from further degradation — amplifying the progressive accumulation. This SAP binding is exploited diagnostically in SAP scintigraphy, a nuclear medicine technique that images the total body amyloid burden.

Why Lambda Is More Amyloidogenic

The thermodynamic stability of the light chain variable domain is the primary determinant of amyloidogenicity. Lambda light chains — particularly those encoded by the IGLV1, IGLV2, and IGLV6 gene families — have conformational flexibility that favors partial unfolding and beta-sheet nucleation under conditions encountered in the interstitial fluids of organs. Kappa light chains tend to form dimers that are more thermodynamically stable, making them less prone to fibril assembly. This explains why lambda-type AL amyloidosis is both more common and generally associated with more severe organ involvement than kappa-type.

Back to Table of Contents

The Heart: The Most Dangerous Organ Involvement

Cardiac involvement is present in approximately 70% of AL amyloidosis patients and is the dominant determinant of prognosis. Unlike many cardiomyopathies, cardiac amyloidosis has unique features that make it both diagnostically distinctive and therapeutically treacherous.

How Amyloid Damages the Heart

Amyloid fibrils infiltrate between myocardial cells throughout the heart — ventricles, atria, valves, conduction system, and autonomic nerves. This infiltration is not true muscle hypertrophy: the myocytes themselves are not enlarged and may actually atrophy under the pressure of amyloid accumulation. The amyloid material has no contractile or electrical function. It makes the heart walls physically thicker and stiffer, reducing ventricular compliance. The result is restrictive cardiomyopathy — the ventricles cannot fill normally in diastole, cardiac output falls, and elevated filling pressures back up into the pulmonary and systemic venous systems, producing the syndrome of heart failure with preserved ejection fraction (HFpEF).

The Low Voltage Paradox

One of the most diagnostically important features of cardiac amyloidosis is the dissociation between the electrocardiogram (ECG) and the echocardiogram. The ECG shows low voltage — small QRS complexes — because amyloid fibrils (which replace myocytes) do not conduct electrical current. Meanwhile, the echocardiogram shows markedly thickened ventricular walls from amyloid deposition. In hypertensive heart disease or hypertrophic cardiomyopathy (the two most common mimics of echocardiographic wall thickening), the QRS voltage is normal or increased because the thickening reflects true muscle hypertrophy that conducts electricity normally. The combination of low ECG voltage plus echocardiographic "hypertrophy" is highly suggestive of infiltrative cardiomyopathy, and cardiac amyloidosis is the leading consideration. The classic echocardiographic description of "granular sparkling" — a speckled, hyperrefractile appearance of the myocardium — was historically considered pathognomonic, though it is now recognized to be a low-sensitivity finding that can occur in other conditions.

Key Echocardiographic Features

Cardiac Biomarkers and Staging

NT-proBNP (N-terminal pro-B-type natriuretic peptide) and cardiac troponin (troponin T or I) are the primary biomarkers of cardiac amyloid burden and are the foundation of the Mayo staging systems. NT-proBNP rises as ventricular filling pressures increase; troponin rises as myocytes are damaged by amyloid infiltration. Both biomarkers independently predict survival and define stage, and both must be assessed at diagnosis and monitored during treatment to track cardiac organ response.

Critical Drug Contraindications

Cardiac amyloidosis changes standard heart failure pharmacology in critical ways. Two drug classes that are standard therapies in other forms of heart failure are contraindicated:

The principal pharmacological therapies for fluid management in cardiac amyloidosis are loop diuretics (furosemide, torsemide), sometimes combined with aldosterone antagonists, used carefully to offload volume without reducing preload excessively.

Back to Table of Contents

Kidney Involvement: Nephrotic Syndrome

Renal involvement occurs in approximately 60–70% of AL amyloidosis patients. The kidney is the second most commonly affected organ after the heart, and renal disease significantly affects quality of life and prognosis.

Glomerular Amyloid Deposition

Amyloid fibrils preferentially deposit in the glomerular mesangium and basement membrane of the kidney. This deposition physically expands the mesangium with acellular amyloid material and disrupts the normal filtration barrier of the glomerular capillary wall. The glomerular filtration barrier normally prevents large proteins — including albumin — from passing into the urine. Amyloid disruption allows massive protein leak into the filtrate.

Nephrotic Syndrome

The resulting clinical picture is nephrotic syndrome: heavy proteinuria (typically >3.5 grams per day, often much higher — 10–20 grams per day is not uncommon in AL amyloidosis), hypoalbuminemia (from urinary albumin losses exceeding the liver's synthetic capacity), edema and anasarca (from reduced oncotic pressure), hyperlipidemia and lipiduria (compensatory hepatic lipoprotein overproduction). Patients may present with severe, pitting edema of the legs, ascites, and pleural effusions. The combination of nephrotic edema and cardiac amyloid-related fluid retention can produce profound volume overload that is difficult to manage.

Progression to Chronic Kidney Disease

Progressive glomerular amyloid deposition reduces the number of functioning nephrons. Serum creatinine rises and the glomerular filtration rate declines. Without effective treatment of the underlying plasma cell clone, the majority of patients with significant renal AL amyloidosis progress to end-stage renal disease (ESRD) requiring dialysis. Achieving a deep hematologic response (CR or VGPR) can stabilize renal function and in some patients produce modest improvement in proteinuria, but complete reversal of established amyloid deposits is slow and often incomplete in the kidney.

The 24-hour urine protein measurement and estimated GFR are tracked as markers of renal organ response during therapy, in addition to the serum free light chain and cardiac biomarker response.

Back to Table of Contents

Neurological Manifestations

Nervous system involvement affects approximately 20–40% of AL amyloidosis patients. Neurological symptoms can be among the most disabling features of the disease and may predate the diagnosis by years.

Peripheral Neuropathy

The most common neurological manifestation is a sensorimotor peripheral neuropathy that is length-dependent — symptoms begin in the feet and ascend over time toward the knees, eventually reaching the hands in a classic "stocking-glove" distribution. Amyloid fibrils deposit around peripheral nerve fibers, directly compressing axons and disrupting the blood-nerve barrier. The neuropathy has two components:

Autonomic Neuropathy

Autonomic nervous system involvement is common and can be more disabling than the sensorimotor neuropathy. Amyloid deposits in autonomic ganglia and sympathetic nerve terminals impair the body's ability to regulate blood pressure, heart rate, bowel function, bladder function, and sweating. The most clinically important manifestation is orthostatic hypotension — a fall in blood pressure of 20 mmHg systolic (or 10 mmHg diastolic) within 3 minutes of standing. Severe orthostatic hypotension causes syncope, falls, and extreme fatigue. It is particularly dangerous in patients with concurrent cardiac amyloidosis who are also being treated with diuretics.

Other autonomic features include early satiety and gastroparesis (from gastric autonomic denervation), alternating constipation and diarrhea, bladder dysfunction (retention or incontinence), erectile dysfunction, and anhidrosis.

Carpal Tunnel Syndrome as an Early Warning

Carpal tunnel syndrome — compression of the median nerve at the wrist — can precede the diagnosis of AL amyloidosis by months to years. Amyloid infiltration of the flexor retinaculum and tenosynovium at the carpal tunnel produces a bulky infiltrative compression of the median nerve. Bilateral carpal tunnel syndrome in a patient who does not have an obvious mechanical explanation (obesity, hypothyroidism, repetitive strain) should prompt consideration of amyloidosis. Similarly, lumbar spinal stenosis from ligamentum flavum amyloid deposition is increasingly recognized as a presenting feature.

Back to Table of Contents

Recognizing AL Amyloidosis: The Visible Signs

AL amyloidosis can produce striking physical findings that, when present, are virtually diagnostic. These visible signs reflect amyloid deposition in specific superficial structures — soft tissues, blood vessel walls, and lymphoid organs.

Macroglossia: The Enlarged Tongue

Macroglossia — abnormal enlargement of the tongue from amyloid infiltration — is the most recognizable and diagnostically powerful sign in AL amyloidosis. The tongue enlarges progressively as amyloid deposits replace normal muscle fibers. Characteristic features include indentations (dental notching or scalloping) along the lateral borders from pressure against the teeth, restricted tongue mobility, and firmness on palpation. Macroglossia can cause progressive difficulties with speech (dysarthria), swallowing (dysphagia), and sleep (obstructive sleep apnea from the enlarged tongue occluding the posterior oropharynx). Macroglossia occurs in approximately 15% of AL amyloidosis patients and is essentially pathognomonic — it is not seen in AA amyloidosis or transthyretin (TTR) amyloidosis, and its presence in a patient with monoclonal protein should prompt urgent evaluation for AL amyloidosis.

Periorbital Purpura: Raccoon Eyes

Periorbital purpura — spontaneous bruising around the eyes, often bilateral, producing the characteristic "raccoon eyes" or "panda eyes" appearance — is another near-pathognomonic finding in AL amyloidosis. Amyloid deposits in the walls of periorbital microvasculature weaken the blood vessel walls. Trivial trauma — sneezing, coughing, a Valsalva maneuver, or even vigorous crying — causes these fragile vessels to rupture and blood to extravasate into the periorbital soft tissue. The bruising can appear spontaneously after sleep. Periorbital purpura can also appear on the eyelids, forehead, and neck in the same distribution. Skin biopsy of involved skin or even apparently normal periorbital skin frequently demonstrates amyloid deposits and can be used diagnostically.

The Shoulder Pad Sign

The shoulder pad sign refers to symmetric enlargement of the shoulder regions from amyloid deposition in shoulder joint capsules, bursae, and periarticular soft tissues. The shoulders appear visually enlarged and feel firm. Patients describe stiffness and limited range of motion. This finding was named because the bilateral swelling resembles the shoulder pads worn in American football uniforms. When present, the shoulder pad sign is a strong clinical clue to systemic amyloidosis.

Skin Changes and Nail Involvement

Skin manifestations beyond periorbital purpura include waxy papules and plaques (from dermal amyloid deposits, particularly in the face, neck, and flexural areas), easy bruising at minor trauma sites anywhere on the body, and rarely dystrophic nails. The skin involvement reflects widespread dermal amyloid deposition and increased capillary fragility.

Back to Table of Contents

Diagnosis: Tissue Biopsy and Congo Red Stain

The diagnosis of AL amyloidosis requires two sequential steps: first, confirming the presence of amyloid deposits by tissue biopsy; second, determining that the amyloid is composed of immunoglobulin light chains (AL type) rather than one of the more than 30 other proteins that can form amyloid in different diseases.

Tissue Biopsy and Congo Red Staining

Amyloid deposits are identified in tissue by the Congo red stain. Under routine light microscopy, amyloid stains salmon-pink with Congo red. The definitive diagnostic finding is apple-green birefringence when Congo-red-stained tissue is viewed under polarized light — amyloid fibrils rotate polarized light in a distinctive way that produces this characteristic apple-green color. No other tissue component shows this optical property; apple-green birefringence under polarized light after Congo red staining is diagnostic of amyloid deposits, regardless of protein type.

Biopsy Site Selection

The choice of biopsy site balances diagnostic yield against procedural risk. The two safest and most commonly used first-line sites are:

Organ biopsies (kidney, liver, rectal mucosa, cardiac) offer higher sensitivity for the specific organ involved but carry greater procedural risk. Cardiac biopsy is reserved for situations where fat pad and bone marrow biopsies are negative but cardiac amyloidosis remains strongly suspected; the sensitivity of cardiac biopsy exceeds 95% but carries a small but real risk of perforation and hemorrhage.

Amyloid Typing: The Critical Second Step

Confirming amyloid by Congo red staining establishes that amyloid is present but does not establish the type. AL amyloidosis must be distinguished from:

Amyloid typing by immunohistochemistry (IHC) using antibodies against specific proteins is performed at most centers but has limitations — IHC can fail to type in up to 15–20% of cases. The gold standard for amyloid typing is laser microdissection mass spectrometry (LMD/MS), in which amyloid deposits are physically microdissected from tissue sections and subjected to proteomic analysis that identifies the constituent proteins with near-100% specificity. LMD/MS is now available at major amyloidosis reference centers and should be used whenever IHC is inconclusive or when clinical features do not fit the suspected type.

Serum Studies to Detect the Plasma Cell Clone

The following serum tests are essential to detect and characterize the clonal plasma cell population in AL amyloidosis:

Cardiac MRI

Cardiac magnetic resonance imaging (MRI) with gadolinium contrast provides highly sensitive imaging evidence of cardiac amyloidosis. Two key findings are characteristic:

Back to Table of Contents

Staging: Mayo 2004 and Mayo 2012 Systems

Staging in AL amyloidosis is primarily cardiac-based because cardiac involvement dominates prognosis. Two Mayo Clinic staging systems have become the international standards.

Mayo 2004 Staging System

The original Mayo 2004 staging system uses two cardiac biomarkers — cardiac troponin T (cTnT) and B-type natriuretic peptide (BNP) — to define three prognostic stages:

The Mayo 2004 system was validated in a pre-modern therapy cohort and served as the basis for trial enrollment and stratification for over a decade.

Mayo 2012 Revised Staging System

The Mayo 2012 system extends the original by adding the serum free light chain difference (dFLC) — the difference between involved and uninvolved serum free light chains — as a third variable. This addition creates a four-stage system that better stratifies high-risk patients:

Stage IV represents the highest-risk patients: advanced cardiac disease plus a large, rapidly producing plasma cell clone. Historically, Stage IV patients often died before they could benefit from chemotherapy. Modern treatment — particularly daratumumab-based combination therapy — has substantially improved Stage IV outcomes compared to these historical figures, with median survival now exceeding 20 months in some contemporary series. Nonetheless, Stage IV remains a medical emergency requiring urgent treatment initiation at a center with amyloidosis expertise.

European Modification

The European modification of the Mayo staging system adds renal staging as a parallel stratification: renal stage is determined by eGFR and 24-hour proteinuria. Renal stage provides additional prognostic information independent of cardiac stage, helping to predict risk of dialysis-dependence and guiding autologous stem cell transplant eligibility decisions.

Back to Table of Contents

Treatment: Eliminating the Plasma Cell Clone

The central principle of AL amyloidosis treatment is straightforward but demanding: eliminate or suppress the plasma cell clone that produces misfolded light chains. Once light chain production stops, no new amyloid is deposited. Existing amyloid deposits may slowly resorb (partial regression is possible and has been documented by imaging), and organs that have not yet been permanently destroyed can partially recover function. The depth of hematologic response — how completely the plasma cell clone is eradicated — is the single most important predictor of organ response and survival.

Hematologic Response Definitions

Response is measured by serial serum free light chain assays. Standard response categories (defined by the International Society of Amyloidosis) are:

Organ response (improvement in cardiac or renal function) typically lags behind hematologic response by 3–12 months. A deep hematologic response (CR or VGPR) is necessary but not always sufficient — some organs with severe amyloid burden do not recover even after the clone is eradicated.

Daratumumab + CyBorD: The Current Frontline Standard

The landmark ANDROMEDA trial (Palladini et al., 2021, N Engl J Med) established subcutaneous daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) as the standard frontline treatment for newly diagnosed AL amyloidosis. In this phase 3 trial of 388 patients, Dara-CyBorD achieved a hematologic CR rate of 53% versus 18% with CyBorD alone — nearly tripling the complete response rate. Organ response rates, progression-free survival, and overall survival all favored the daratumumab arm. The FDA approved daratumumab for AL amyloidosis in January 2021 based on these results.

Daratumumab is a human anti-CD38 monoclonal antibody. It targets CD38, a surface protein expressed at high levels on clonal plasma cells (and on normal plasma cells). Daratumumab kills plasma cells through multiple mechanisms: complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent phagocytosis, and induction of apoptosis. Added to the standard CyBorD backbone (cyclophosphamide — alkylating agent; bortezomib — proteasome inhibitor; dexamethasone — corticosteroid), it produces deeper and more durable plasma cell elimination.

Autologous Stem Cell Transplant (ASCT)

Autologous stem cell transplant — in which high-dose melphalan chemotherapy is used to ablate the bone marrow followed by re-infusion of the patient's own previously collected stem cells — can produce deep hematologic responses (CR rates of 40–50%) and prolonged remissions in appropriately selected patients. However, only approximately 20–25% of AL amyloidosis patients at diagnosis are eligible for ASCT. Eligibility is restricted by cardiac function (ejection fraction >40–45%, no severe diastolic dysfunction), age (typically <70), performance status, renal function, and other organ involvement criteria. The high-dose melphalan conditioning carries significant treatment-related mortality, particularly in patients with cardiac amyloidosis, where the rate can reach 5–15% at less experienced centers. Patients should be evaluated for ASCT at a specialized amyloidosis center with high transplant volume.

In the contemporary era, many transplant-eligible patients receive a brief course of Dara-CyBorD induction first to reduce the plasma cell clone burden before proceeding to ASCT — a strategy that may deepen post-transplant responses.

CyBorD and Other Bortezomib-Based Regimens

Before daratumumab approval, CyBorD (cyclophosphamide + bortezomib + dexamethasone) was the standard frontline regimen for non-transplant-eligible patients. It remains the backbone of current therapy. Bortezomib, a first-generation proteasome inhibitor, is particularly effective in AL amyloidosis because plasma cells are highly dependent on proteasome function to manage the large burden of misfolded protein they produce — proteasome inhibition creates lethal proteotoxic stress in the plasma cell. Bortezomib is given subcutaneously (SC) to reduce peripheral neuropathy risk compared to the original IV formulation.

Melphalan-Based Therapy

Oral melphalan plus dexamethasone (MDex) was for many years the standard non-transplant regimen and remains a treatment option for fragile or elderly patients who cannot tolerate bortezomib or daratumumab. Response rates with MDex are lower than with CyBorD-based regimens, and it has largely been supplanted in practice.

Supportive Care

Aggressive supportive care is essential in parallel with anti-plasma-cell therapy:

Back to Table of Contents

Organ Recovery and Long-Term Outcomes

One of the most remarkable — and clinically important — aspects of AL amyloidosis is that organ damage is not entirely irreversible. Sustained deep hematologic response creates conditions for gradual amyloid regression and partial organ recovery.

Mechanisms of Amyloid Regression

When new light chain production is halted by effective plasma cell eradication, the thermodynamic equilibrium between fibril formation and dissolution shifts toward dissolution. Macrophages and other immune cells can slowly phagocytose amyloid fibrils over months to years. The rate of amyloid regression varies by organ: the liver can show substantial improvement within 6–12 months of deep hematologic response; the kidney regressess more slowly over 1–3 years; cardiac amyloid regresses the most slowly, often requiring 2 years or more of sustained remission before measurable cardiac improvement is seen on imaging.

Monitoring Organ Response

Organ response is defined separately for each organ:

Long-Term Survival in the Modern Era

In patients who achieve hematologic CR after frontline treatment, median overall survival now exceeds 10 years in some series — a dramatic improvement from the historical median of 12–15 months for all-comers. Patients achieving VGPR also have significantly improved survival compared to those achieving only partial response. The single most important predictor of long-term outcome is achieving the deepest possible hematologic response as quickly as possible — before irreversible organ damage occurs.

Long-term complications in survivors include chronic kidney disease (in those with significant renal involvement), persistent neuropathy (amyloid deposits in peripheral nerves regress slowly), and occasional late relapses when the plasma cell clone re-emerges. Monitoring with serial sFLC assays every 3–6 months is recommended indefinitely for all patients in remission to detect early biochemical relapse before clinical relapse occurs.

Back to Table of Contents

Liver and Gastrointestinal Involvement

Amyloid deposition in the liver and gastrointestinal tract occurs in a significant minority of AL amyloidosis patients and adds to the complexity of clinical management.

Hepatic Amyloidosis

Liver involvement typically manifests as hepatomegaly (the liver enlarges as amyloid replaces hepatocytes and expands the hepatic sinusoids), along with a cholestatic pattern of liver function abnormalities. The most characteristic laboratory finding is a markedly elevated alkaline phosphatase (ALP) — disproportionate to other liver enzymes. Bilirubin is typically only mildly elevated unless very advanced. Aminotransferases (AST and ALT) may be normal or modestly elevated. Severe hepatic amyloidosis can cause synthetic dysfunction (low albumin, prolonged prothrombin time), portal hypertension with ascites, and in rare cases hepatic rupture (a life-threatening emergency from sub-capsular amyloid deposits). Hepatic amyloidosis is one of the strongest predictors of poor prognosis in AL amyloidosis independent of cardiac stage.

Gastrointestinal Amyloidosis

The gastrointestinal tract from esophagus to rectum can be involved by amyloid deposits. GI manifestations include:

The rectal mucosa has historically been used as a biopsy site for amyloidosis diagnosis precisely because rectal amyloid deposits (particularly in the submucosal vessels and lamina propria) are common even when GI symptoms are absent. Rectal biopsy sensitivity is approximately 80–85% in systemic AL amyloidosis.

Back to Table of Contents

Research Papers

The following PubMed citations cover pivotal studies on AL amyloidosis, including the ANDROMEDA trial, staging systems, pathogenesis, and treatment advances.

Back to Table of Contents

Connections

Back to Table of Contents